Matt Loose is a computational biologist and Director of the DeepSeq sequencing facility at the University of Nottingham, where he leads the development of rapid long-read sequencing approaches for clinical genomics. His work focuses on transforming central nervous system (CNS) tumour diagnostics through the application of real-time nanopore sequencing and methylation profiling.
He has played a leading role in developing workflows that combine intraoperative methylation classification with comprehensive next-day molecular profiling from a single assay, integrating tumour classification, copy-number analysis, structural variant detection, gene fusion analysis, and clinically relevant methylation markers. His research has contributed to the translation of Oxford Nanopore Technologies into clinically deployable neuro-oncology diagnostics, particularly through the development of near-patient sequencing strategies capable of supporting rapid clinical decision-making.
Matt is actively involved in national efforts to establish harmonised long-read sequencing pathways across the NHS, including work on validation, quality assurance, and service delivery models for CNS tumour testing. His broader interests include adaptive sequencing (“Read Until”), scalable genomic infrastructure, and the integration of real-time genomics into routine clinical care.